drugset / Trial / NCT01653314

Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers

NCT01653314

Phase 1 Completed 40 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.

Timeline

Start
2012-01
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 400 mg

Indications

No indication recorded.